Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/14/24
End: 10/30/25
Due: 10/30/26
Phase: N/A
Priority: Normal
Start: 05/30/22
End: 11/15/27
Due: 11/15/28
Phase: N/A
Priority: Normal
Start: 03/31/22
End: 10/12/24
Due: 10/12/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma | NCT06727630 | Zhuhai Yufan Biotechnologies Co., Ltd | user2@example.com | None | 2024-03-14 | 2025-10-30 | 2026-10-30 | - | - | 2025-07-14 |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | NCT05315167 | Zhuhai Yufan Biotechnologies Co., Ltd | user2@example.com | None | 2022-05-30 | 2027-11-15 | 2028-11-15 | - | - | 2025-07-14 |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors | NCT05159700 | Zhuhai Yufan Biotechnologies Co., Ltd | user2@example.com | None | 2022-03-31 | 2024-10-12 | 2025-10-12 | - | - | 2025-07-14 |